Key Points
- Insider sale: Stoke Therapeutics insider Barry Ticho sold 1,795 shares on June 1 at an average price of $30.58, totaling about $54,891. The transaction was made under a pre-arranged Rule 10b5-1 plan, and his ownership fell by 4.9%.
- Recent trading activity: Ticho has also sold shares in multiple prior transactions in March, indicating a pattern of insider selling over the past few months.
- Company/stock snapshot: STOK shares were up 2.7% and opened at $29.46, while analysts remain broadly positive with an average Moderate Buy rating and an average target price of $41.83.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the transaction, the insider directly owned 34,826 shares in the company, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Barry Ticho also recently made the following trade(s):
- On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24.
- On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total transaction of $203,473.64.
- On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39.
Stoke Therapeutics Stock Up 2.7%
Shares of STOK stock opened at $29.46 on Thursday. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -10.48 and a beta of 1.17. The company's 50 day moving average is $32.70 and its 200 day moving average is $32.32. Stoke Therapeutics, Inc. has a 52-week low of $10.64 and a 52-week high of $40.22.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The business had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. Analysts anticipate that Stoke Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on STOK shares. Wedbush lifted their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an "outperform" rating in a report on Tuesday, March 17th. Chardan Capital reaffirmed a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Wall Street Zen lowered shares of Stoke Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 21st. Guggenheim began coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Wolfe Research began coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They issued an "outperform" rating and a $40.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $41.83.
Get Our Latest Report on Stoke Therapeutics
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. acquired a new position in Stoke Therapeutics during the third quarter valued at $1,062,000. Penserra Capital Management LLC acquired a new position in Stoke Therapeutics during the third quarter valued at $3,539,000. Vanguard Group Inc. lifted its position in Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company's stock valued at $74,351,000 after purchasing an additional 217,616 shares during the period. Baillie Gifford & Co. acquired a new position in Stoke Therapeutics during the fourth quarter valued at $7,837,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in Stoke Therapeutics during the fourth quarter valued at $2,000,000.
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
